Inovio Pharmaceuticals Inc (INO)

[Ubertino]

Inovio and Collaborators Receive NIH Grant
to Evaluate HIV Immunotherapy PENNVAX®-GP’s Ability
to Induce Remission of HIV Infection and End Lifetime
of Drug Therapy


Grant will fund therapeutic clinical studies testing PENNVAX-GP with
INO-9012 (an IL-12 immune activator) alone and with the addition of
a PD-1 checkpoint inhibitor


PLYMOUTH MEETING, Pa. – March 30, 2017 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its academic and industry collaborators received a multi-year $6.95 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to develop a single or combination therapy using Inovio’s PENNVAX-GP with the goal of attaining long-term HIV remission in the absence of antiviral drugs.